🔎 Trials Near Me

Hjem › Eggstokkreft › Minnesota

Kliniske studier for Eggstokkreft i Minnesota

53 studier for Eggstokkreft søker deltakere på steder i Minnesota.

Byer i Minnesota

Offisiell studietekst (engelsk)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Sanford Joe Lueken Cancer Center, Bemidji
  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • og 12 flere
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05564377

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Health Partners Frauenshuh Cancer Center, Saint Louis Park
  • Health Partners Cancer Center at Regions Hospital, Saint Paul
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06172478

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Site 0288 - Minnesota Oncology Hematology - Maplewood, Maplewood
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT05128825

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • University of Minnesota - Minneapolis /ID# 275718, Minneapolis
  • Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT06890338

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Mayo Clinic, Rochester
RekruttererObservasjonsstudie
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT05051722

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Mayo Clinic Rochester, Rochester
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04981119

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Mayo Clinic in Rochester, Minnesota, Rochester
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Mayo Clinic - Rochester, Rochester
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213791

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Mayo Rochester, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07109726

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Masonic Cancer Center, University of Minnesota, Minneapolis
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 15. sep. 2026 · NCT06915025

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Minnesota Oncology-Minneapolis, Minneapolis
RekruttererFase 2
Alder 18 til 99 · Kvinner · Oppdatert 15. sep. 2026 · NCT07023627

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Mayo Clinic (Rochester), Rochester
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • University of Minnesota Masonic Cancer Center, Minneapolis
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07216105

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Minneapolis VA Medical Center, Minneapolis
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06995898

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • University of Minnesota, Minneapolis
RekruttererFase 1
Alder 15 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • University of Minnesota/Masonic Cancer Center, Minneapolis
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Mayo Clinic in Rochester, Rochester
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT07001748

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Minneapolis
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07182149

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Minnesota Oncology - Burnsville, Burnsville
  • Cambridge Medical Center, Cambridge
  • Minnesota Oncology Hematology PA-Chaska, Chaska
  • og 26 flere
Rekrutterer
Alder 35 til 50 · Kvinner · Oppdatert 7. aug. 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health - Baxter Clinic, Baxter
  • Sanford Joe Lueken Cancer Center, Bemidji
  • og 48 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT06580314

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • M Health Fairview University of Minnesota Medical Center, Minneapolis
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06330064

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Minnesota Oncology Hematology, Maplewood
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Minnesota Oncology Hematology, Maple Grove
  • Mayo Clinic (Minnesota), Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT04657068

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • St. Luke's Hospital, Duluth
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

  • 518, Minneapolis
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 16. jul. 2026 · NCT06906341

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • University of Minnesota - Masonic Cancer Center, Minneapolis
  • Mayo Clinic, Rochester
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 14. jul. 2026 · NCT04606914

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

  • Mayo Clinic Methodist Campus, Rochester
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 14. jul. 2026 · NCT05804370

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

  • The Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 18 til 75 · Kvinner · Oppdatert 13. jul. 2026 · NCT07322094

UNTOLD Ovarian Cancer Unmet Needs Survey

  • Masonic Cancer Center, Minneapolis
RekruttererObservasjonsstudie
Alder 18 og eldre · Kvinner · Oppdatert 8. jul. 2026 · NCT07070726

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
  • Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
  • Allina Health Cancer Institute - United Hospital, Saint Paul
  • og 1 flere
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT04389632

Lead-212 PSV359 Therapy for Patients With Solid Tumors

  • Mayo Clinic in Rochester, Minnesota, Rochester
RekruttererFase 1/2
Alder 18 til 90 · Alle kjønn · Oppdatert 6. jul. 2026 · NCT06710756

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

  • Mayo Clinic, Rochester
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 6. jul. 2026 · NCT07226427

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Minnesota Oncology Hematology PA, Minneapolis
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 2. jul. 2026 · NCT06819007

Integrated Cancer Repository for Cancer Research

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health-St. Joseph's Medical Center, Brainerd
  • Essentia Health - Duluth Clinic, Duluth
  • og 2 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 19 til 110 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT02012699

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Mayo Clinic - Rochester, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jun. 2026 · NCT05377996

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • Mayo Clinic Rochester, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jun. 2026 · NCT06051695

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.